This hypothesis is contradicted by observations stemming from a clinical trial of altered peptide ligand (APL) of myelin-basic protein (MBP) in MS, which demonstrated clear expansion of T cells in the CSF at the time of APL-induced CELs (Bielekova et al., 2000). The gene discussed is MBP; the disease is myeloid sarcoma.